Bristol-Myers Squibb (BMY) IV into Wellington says it does not support Bristol-Myers' acquisition of Celgene (CELG)
Bristol-Myers Squibb (NYSE: BMY) March weekly call option implied volatility is at 27, March is at 23; compared to its 52-week range of 17 to 44 into Wellington Management Company LLP recently informed the Board of Directors of Bristol-Myers Squibb that it is not supportive of the company's proposed acquisition of Celgene Corporation (CELG).